CTI BioPharma (CTIC) Receives Analyst Rating

CTI BioPharma (CTIC) has an average broker rating of 3.67, which is interpreted as a Sell, as rated by 3 equity analysts. Nevertheless, the majority of 2 analysts consider that the stock is a Hold with neither a large upside nor a downside. Ranking by Zacks Investment Research for Coach Inc is 2, which is also a Buy. 1 brokerage firm advices Strong Sell on the share due to lack of confidence about the future of the company.


CTI BioPharma (NASDAQ:CTIC): The stock opened in the green at $0.366 on Thursday, but the bulls found it difficult to push the prices higher. The stock reached a high of $0.3749 and a low of $0.36 for the day. The stock did not find buyers even at the lows and closed at $0.3655 recording a loss of -0.98%. 668,086 shares exchanged hands during the trading day. The stock had closed at $0.3691 in the previous days trading.

CTI BioPharma Corp. (CTI), formerly Cell Therapeutics, Inc., is a biopharmaceutical company focused on the acquisition, development and commercialization of targeted therapies covering a spectrum of blood-related cancers that offer a benefit to patients and healthcare providers. The Company is focused on commercializing PIXUVRI (pixantrone), or PIXUVRI, in the European Union, for the treatment of adult patients with multiply relapsed or refractory aggressive B-cell non-Hodgkin lymphoma (NHL), and conducting a Phase III clinical trial program of pacritinib for the treatment of adult patients with myelofibrosis to support regulatory submission for approval in the United States and Europe. It is also engaged in evaluating pacritinib in earlier clinical trials as treatment for other blood-related cancers. Its development product candidates include tosedostat and Opaxio.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *